Diagnosis and treatment of menorrhagia

Acta Obstetricia et Gynecologica Scandinavica

Volumn 86, Issue 6, 2007, Pages 749-757

  Hurskainen, R ^a,f   Grenman, S ^b   Komi, I ^f   Kujansuu, E ^c   Luoto, R ^c   Orrainen, M ^f   Patja, K ^h   Penttinen, J ^d   Silventoinen, S ^f   Tapanainen, J ^e   Toivonen, J ^g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e UNIVERSITY OF OULU   (Finland)

^f HYVINKÄÄ HOSPITAL   (Finland)

^g JORVI HOSPITAL   (Finland)

^h Finska Lo karforeningen Duodecim   (Finland)

Author keywords

Diagnosis; Guidelines; Menorrhagia; Treatment

Indexed keywords

ANTICOAGULANT AGENT; COPPER INTRAUTERINE DEVICE; DESMOPRESSIN; GESTAGEN; GONADORELIN DERIVATIVE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; TRANEXAMIC ACID;

ABDOMINAL DISCOMFORT; AGE DISTRIBUTION; ANEMIA; ARTIFICIAL EMBOLISM; BLEEDING; BLOATING; BREAST TENDERNESS; CANCER DIAGNOSIS; CANCER RISK; DIAGNOSTIC VALUE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSMENORRHEA; ENDOMETRIUM ABLATION; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEEDBACK SYSTEM; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HUMAN; HYPERMENORRHEA; HYSTERECTOMY; HYSTEROGRAPHY; HYSTEROSCOPY; INCIDENCE; INTERMETHOD COMPARISON; MEDICAL SPECIALIST; MENOPAUSAL SYNDROME; MENORRHAGIA; MENSTRUAL CYCLE; NAUSEA; ORAL CONTRACEPTION; OSTEOPOROSIS; OUTPATIENT; OVULATION; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRAINING; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERUS MYOMA; VON WILLEBRAND DISEASE;

FEMALE; HUMANS; MENORRHAGIA; PRACTICE GUIDELINES;

EID: 34249092018     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340701415400     Document Type: Review

References (114)

1. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss - a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45:320-51.
2. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia II: is the 80-ml blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol. 2004;190:1224-9.
3. Whittaker M, Lilford R, Bridgman S, Brown J. The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy. Br Med J. 2004;328:129; erratum in: Br Med J. 2004;328:494.
4. Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane review. CD0002126. In: The Cochrane Library, Issue 2, 2004.
5. Nagele F, O'Connor H, Davies A, Badawy A, Mohamed H, Magos A. 2500 outpatient diagnostic hysteroscopies. Obstet Gynecol. 1996;88:87-92.
6. Vercellini P, Cortesi I, Oldani S, Moschetta M, De Giorgi O, Crosignani PG. The role of transvaginal ultrasonography and outpatient diagnostic hysteroscopy in the evaluation of patients with menorrhagia. Hum Reprod. 1997;12:1768-71.
7. Augustin LS, Gallus S, Bosetti C ym. Glycemic index and glycemic load in endometrial cancer. Int J Cancer. 2003;105:404-7.
8. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11:1531-43.
9. Milsom I, Andersson K, Jonasson K, Lindstedt G, Rybo G. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception. 1995;52:175-9.
10. Rybo G, Andersson K, Odlind V. Hormonal intrauterine devices. Ann Med. 1993;25:143-7.
11. Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol. 1996;53:234-8.
12. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998;351:485-9.
13. Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. Bleeding disorders: a common cause of menorrhagia in adolescents. J Pediatr. 2001;138:856-61.
14. Fraser IS. Menorrhagia-a pragmatic approach to the understanding of causes and the need for investigations. Br J Obstet Gynaecol. 1994;101(Suppl 11):3-7.
15. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol. 1995;85:977-82.
16. Hurskainen R. Vuotohäiriöt. Kirjassa: Lääkärin käsikirja. Kunnamo I, Varonen H, Nyberg P ym. (toim.) 7. uudistettu painos. Hämeenlinna: Kustannus Oy Duodecim, 2004.
17. Dueholm M, Jensen ML, Laursen H, Kracht P. Can the endometrial thickness as measured by transvaginal sonography be used to exclude polyps or hyperplasia in premenopausal patients with abnormal uterine bleeding? Acta Obstet Gynecol Scand. 2001;80:645-51.
18. Dijkhuizen FP, Brolmann HA, Potters AE, Bongers MY, Heintz AP. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol. 1996;87:345-9.
19. Schwarzler P, Concin H, Bosch H ym. An evaluation of sonohysterography and diagnostic hysteroscopy for the assessment of intrauterine pathology. Ultrasound Obstet Gynecol. 1998;11:337-42.
20. Nanda S, Chadha N, Sen J, Sangwan K. Transvaginal sonography and saline infusion sonohysterography in the evaluation of abnormal uterine bleeding. Aust N Z J Obstet Gynaecol. 2002;42:530-4.
21. Dijkhuizen FP, Mol BW, Brolman HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765-72.
22. Hurskainen R, Halmesmäki E, Rasi V, Mäkipernaa A. Nainen ja von Willebrandtin tauti. Duodecim. 2003;119:33-40.
23. Lethaby A, Augood C, Duckitt K. Nonsteroidal antiinflammatory drugs for heavy menstrual bleeding. Cochrane Review. CD000400. In: The Cochrane Library, Issue 4, 2003.
24. Lindoff C, Rybo G, Asted B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost. 1993;70:238-40.
25. Rydin E, Lundberg PO. Letter: tranexamic acid and intracranial thrombosis. Lancet. 1976;2:49.
26. Rybo G. Tranexamic acid therapy effective treatment in heavy menstrual bleeding: clinical updata on safety. Ther Adv. 1991;4:1-8.
27. Marjoribanks J, Proctor ML, Farquhar C. Nonsteroidal antiinflammatory drugs for primary dysmenorrhoea. Cochrane Review. CD001751. In: The Cochrane Library, Issue 4, 2003.
28. Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Review. CD000154. In: The Cochrane Library, Issue 1, 2004.
29. Miller L, Huges JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101:653-61.
30. Anderson F, Hait H. A multicenter, randomized study on an extended cycle oral contraceptive. Contraception. 2003;68:89-96; erratum in: Contraception. 2004;69:175.
31. Lee C. Women and von Willebrand disease. Hemophilia. 1999;5(Suppl):38-45.
32. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Review. CD003855. In: The Cochrane Library, Issue 2, 2004.
33. Hurskainen R, Teperi J, Rissanen P ym. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004;291:1456-63.
34. Mansour M, Mansour D. The effectiveness of the levonorgestrel intrauterine system (LNG-IUS) in the treatment of dysmenorrhea in a district clinic for abnormal uterine bleeding. Br J Obstet Gynacol. 1998;105(suppl 17):323.
35. Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol. 1997;104:614-6.
36. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med. 2001;19:355-63.
37. Veldhuis HM, Vos AG, Lagro-Janssen AL. Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract. 2004;10:82-7.
38. Järvelä I, Tekay A, Jouppila P. The effect of a levonorgestrel-releasing intrauterine system on uterine atrery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod. 1998;13:3379-83.
39. Inki P, Hurskainen R, Palo P ym. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol. 2002;20:381-5.
40. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004;69:407-12.
41. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998;105:592-8.
42. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. 1999;93:233-8.
43. Rybo G, Andersson K. IUD use and endometrial bleedings. In: Bardin CW, Mishell DR Jr (toim.) Proceedings from the Fourth International Conference on IUDs. Newton: Butterworth-Heinemann, 1994, pp. 210-8.
44. Sivin I. International experience with Norplant and Norplant-2 contraceptives. Stud Fam Plann. 1988;19:81-94.
45. Fernandez H, Kadoch O, Capella-Allouc S, Gervaise A, Taylor S, Frydman R. Hysteroscopic resection of submucous myomas: long term results. French Ann Chir. 2001;126:58-64.
46. Wamsteker K, Emanuel MH, de Kruif JH. Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet Gynecol. 1993;82:736-40.
47. Vercellini P, Zaina B, Yaylayan L, Pisacreta A, De Giorgi O, Crosignani PG. Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Obstet Gynecol. 1999;94:341-7.
48. Hart R, Molnár BG, Magos A. Long term follow up of hysteroscopic myomectomy assessed by survival analysis. Br J Obstet Gynaecol. 1999;106:700-5.
49. Emanuel MH, Wamsteker K, Hart AA, Metz G, Lammes FB. Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding. Obstet Gynecol. 1999;93:743-8.
50. DeWaay DJ, Syrop CH, Nygaard I, Davis WA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol. 2002;100:3-7.
51. Perez-Medina T, Martinez O, Folgueira G, Bajo J. Which endometrial polyps should be resected? J Am Assoc Gynecol Laparosc. 1999;6:71-4.
52. Cravello L, Stolla V, Bretelle F, Roger V, Blanc B. Hysteroscopic resection of endometrial polyps: a study of 195 cases. Eur J Obstet Gynecol Reprod Biol. 2000;93:131-4.
53. Savelli L, De Iaco P, Santini D ym. Histopathologic features and risk factors for benignity, hyperplasia and cancer in endometrial polyps. Am J Obstet Gynecol. 2003;188:927-31.
54. Jansen FW, Vredevoogd CB, Van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol. 2000;96:266-70.
55. Bradley LD. Complications in hysteroscopy: prevention, treatment and legal risk. Curr Opin Obstet Gynecol. 2002;14:409-15.
56. Phillips DR, Nathanson HG, Meltzer SM, Milim SJ, Haselkorn JS, Johnson P. Transcervical electrosurgical resection of submucous leiomyomas for chronic menorrhagia. J Am Assoc Gynecol Laparosc. 1995;2:147-53; erratum in: J Am Assoc Gynecol Laparosc. 1995;2:496.
57. Kuppermann M, Varner RE, Summitt R Jr ym. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning the medicine or surgery (Ms) randomized trial. JAMA. 2004;291:1447-55.
58. Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol. 1997;90:257-63.
59. Sculpher MJ, Bryan S, Dwyer N, Hutton J, Stirrat GM. An economic evaluation of transcervical endometrial resection versus abdominal hysterectomy for the treatment of menorrhagia. Br J Obstet Gynaecol. 1993;100:244-52.
60. Lethaby A, Shepperd S, Cooke I, Farguhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. CD000329. In: The Cochrane Library, Issue 2, 2004.
61. Alexander DA, Naji AA, Pinion SB ym. Randomised trial comparing hysterectomy with endometrial ablation for dysfunctional uterine bleeding: psychiatric and psychosocial aspects. Br Med J. 1996;312:280-4.
62. Meltomaa SS, Mäkinen JI, Taalikka MO, Helenius HY. One-year cohort of abdominal, vaginal, and laparoscopic hysterectomies: complications and subjective outcomes. J Am Coll Surg. 1999;189:389-96.
63. Maia H Jr, Maltez A, Coelho G, Athayde C, Coutinho EM. Insertion of mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc. 2003;10:512-6.
64. Abbott J, Hawe J, Hunter D, Garry R. A double-blind randomized trial comparing the Cavaterm and the NovaSure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertil Steril. 2003;80:203-8.
65. Agnelli G, Gresele P, De Cunto M, Gallai V, Nenci GG. Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis. Case report. Br J Obstet Gynaecol. 1982;89:681-2.
66. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand. 1988;67:645-8.
67. Bettocchi S, Ceci O, Vicino M, Marello F, Impedovo L, Selvaggi L. Diagnostic inadequacy of dilatation and curettage. Fertil Steril. 2001;75:803-5.
68. Bianchi S, Fedele L, Vignali M, Galbiati E, Cherubini R, Ortolani S. Effects on bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas. Calcif Tissue Int. 1995;57:78-80.
69. Bonduelle M, Walker JJ, Calder AA. A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgrad Med J. 1991;67:833-6.
70. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Br Med J. 1996;313:579-82.
71. Brinton LA, Berman ML, Mortel R ym. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167:1317-25.
72. Brooks PG, Loffer FD, Serden SP. Resectoscopic removal of symptomatic intrauterine lesions. J Reprod Med. 1989;34:435-7.
73. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J. 1970;4:214-6.
74. Cameron IT, Haining R, Lumsden MA, Thomas VR, Smith SK. The effects of mefenamic acid and noretisterone on measured menstrual blood loss. Obstet Gynecol. 1990;76:85-8.
75. Cameron IT, Leask R, Kelly RW, Baird DT. The effects of danazol, mefenamic acid, noretisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins. 1987;34:99-110.
76. Cameron IT. Dysfunctional uterine bleeding. Baillieres Clin Obstet Gynaecol. 1989;3:315-27.
77. Cann CE. Bone densitometry as an adjunct to GnRH agonist therapy. J Reprod Med. 1998;43(3 Suppl):321-30.
78. Cook JR, Seman EI. Pregnancy following endometrial ablation: case history and literature review. Obstet Gynecol Surv. 2003;58:551-6.
79. Cooper J, Gimpelson R, Laberge P ym. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002;9:418-28.
80. Crosignani PG, Vercellini P, Apolone G, De Giorgi O, Cortesi I, Meschia M. Endometrial resection versus vaginal hysterectomy for menorrhagia: long-term clinical and quality-of-life outcomes. Am J Obstet Gynecol. 1997;177:95-101.
81. Davies D, Howell DA. Tranexamic acid and arterial thrombosis. Lancet. 1977;1:49.
82. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol. 1989;96:840-4.
83. Dueholm M, Forman A, Jensen ML, Laursen H, Kracht P. Transvaginal sonography combined with saline contrast sonohysterography in evaluating the uterine cavity in premenopausal patients with abnormal uterine bleeding. Ultrasound Obstet Gynecol. 2001;18:54-61.
84. Edlund M, Andersson K, Rybo G, Lindoff C, Astedt B, von Schoultz B. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol. 1995;102:913-7.
85. El-Toukhy T, Hefni M. Pregnancy after hydrothermal endometrial ablation and laparoscopic sterilisation. Eur J Obstet Gynecol Reprod Biol. 2003;106:222-4.
86. Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001;80:1131-6.
87. Farquhar CM, Lethaby A, Sowter M, Verry J, Baranyai J. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol. 199;181:525-9.
88. Fothergill DJ, Brown VA, Hill AS. Histological sampling of the endometrium-a comparison between formal curettage and the Pipelle sampler. Br J Obstet Gynaecol. 1992;99:779-80.
89. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991;31:66-70.
90. Hall P, Maclachlan N, Thorn N, Nudd MW, Taylor CG, Garrioch DB. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol. 1987;94:554-8.
91. Halmesmäki K, Hurskainen R, Tiitinen A ym. A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod. 2004;19:378-82.
92. Hashimoto S, Koike T, Tatewaki W ym. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia. 1994;8:1113-5.
93. Hawe J, Abbott J, Hunter D, Phillips G, Garry R. A randomized controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the dysfunctional uterine bleeding. BJOG. 2003;110:350-7.
94. Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol. 1993;169:1134-9.
95. Hurskainen R, Teperi J, Rissanen P ym. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet. 2001;357:273-7.
96. Kir M, Hanlon-Lundberg KM. Successful pregnancy after thermal balloon endometrial ablation. Obstet Gynecol. 2004;103:1070-3.
97. Krassas GE, Pontikides N, Kaltsas T ym. Disturbances of menstruation in hypothyroidism. Clin Endocrinol. 1999;50:655-9.
98. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Review. CD000249. In: The Cochrane Library, Issue 4, 2003.
99. Lethaby A, Hickey M. Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Review. CD001501. In: The Cochrane Library, Issue 1, 2004.
100. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Review. CD001016. In: The Cochrane Library, 2004.
101. Levi F, La Vecchia C, Negri E, Parazzini F, Franceschi S. Body mass at different ages and subsequent endometrial cancer risk. Int J Cancer. 1992;50:567-71.
102. Loffer FD, Grainger D. Five-year follow-up of patients participating in a randomized trial of uterine balloon therapy versus rollerball ablation for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002;9:429-35.
103. Munoz JL, Jimenez JS, Hernandez C ym. Hysteroscopic myomectomy: our experience and review. JSLS. 2003;7:39-48.
104. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995;102:401-6.
105. Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynaecol. 1984;91:913-6.
106. Sowter MC, Lethaby A, Singla AA. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding. Cochrane Review. CD001124. In: The Cochrane Library, Issue 3, 2002.
107. Tahir MM, Bibrigg MA, Browning JJ, Brookes ST, Smith PA. A randomised controlled trial comparing transvaginal ultrasound, outpatient hysteroscopy and endometrial biopsy with inpatient hysteroscopy and curettage. Br J Obstet Gynaecol. 1999;106:1259-64.
108. Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol. 2002;68:307-9.
109. van Eijkeren MA, Christiaens GC, Geuze HJ, Haspels AA, Sixma JJ. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol. 1992;166:1419-28.
110. van Zon-Rabelink IA, Vleugels MP, Merkus HM, de Graaf R. Endometrial ablation by rollerball eleotrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. Eur J Obstet Gynecol Reprod Biol. 2003;110:220-3.
111. Vihko KK, Raitala R, Taina E. Endometrial thermoablation for treatment of menorrhagia: comparison of two methods in outpatient setting. Acta Obstet Gynecol Scand. 2003;82:269-74; erratum in: Acta Obstet Gynecol Scand. 2003;82:1156.
112. Wilansky DL, Greisman B. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol. 1989;160:673-7.
113. Woo KS, Tse LK, Woo JL, Vallance-Owen J. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract. 1989;43:465-6.
114. Indman PD. Hysteroscopic treatment of menorrhagia associated with uterine leiomyomas. Obstet Gynecol. 1993;81:716-20.